1. In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses
   Matin Kayyal et al, 2021, Molecular Biotechnology CrossRef
2. Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact
   Kuan-Yin Shen et al, 2015, Expert Review of Vaccines CrossRef
3. Mobilizing and evaluating anticancer T cells: pitfalls and solutions
   Céline Robert-Tissot et al, 2013, Expert Review of Vaccines CrossRef
4. Emerging self-assembling peptide nanomaterial for anti-cancer therapy
   Lisheng Zhu et al, 2021, Journal of Biomaterials Applications CrossRef
5. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors
   Darin A. Wick et al, 2011, Vaccine CrossRef
6. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy
   ROMANA MIKYŠKOVÁ et al, 2016, International Journal of Oncology CrossRef
7. Harnessing Nanoparticles for Immunomodulation and Vaccines
   Ariane Gomes et al, 2017, Vaccines CrossRef
8. Dendritic cell-based vaccines for the therapy of experimental tumors
   Elzbieta Pajtasz-Piasecka et al, 2010, Immunotherapy CrossRef
9. Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model
   Cunbao Liu et al, 2018, Human Vaccines & Immunotherapeutics CrossRef
10. Development of HPV16,18,31,45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools
    Ali Namvar et al, 2020, Biotechnology Letters CrossRef
11. Display of DNA on Nanoparticles for Targeting Antigen Presenting Cells
    Nicholas M. Molino et al, 2017, ACS Biomaterials Science & Engineering CrossRef
12. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice
    Romana Mikyskova et al, 2017, OncoImmunology CrossRef
13. SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies
    Lanxiang Huang et al, 2021, Asian Journal of Pharmaceutical Sciences CrossRef
14. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect
    Jianqiang Li et al, 2017, Vaccine CrossRef
15. MHC Class I Molecules and Cancer Progression: Lessons Learned from Preclinical Mouse Models
    Irene Romero et al, 2020, Cancer Immunology CrossRef
16. Immunotherapy of MHC class I-deficient tumors
    Milan Reiniš, 2010, Future Oncology CrossRef
17. MHC Class I Molecules and Cancer Progression: Lessons Learned from Preclinical Mouse Models
    Irene Romero et al, 2015, Cancer Immunology CrossRef
18. Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform
    Célia Jacoberger-Foissac et al, 2019, International Journal of Pharmaceutics CrossRef
19. Development of multiepitope therapeutic vaccines against the most prevalent high-risk human papillomaviruses
    Heidar Ali Panahi et al, 2020, Immunotherapy CrossRef
20. Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors
    Cunbao Liu et al, 2018, International Journal of Pharmaceutics CrossRef
21. A comprehensive in silico analysis for identification of therapeutic epitopes in HPV16, 18, 31 and 45 oncoproteins
    Heidar Ali Panahi et al, 2018, PLOS ONE CrossRef
22. MHC Class I Expression in Experimental Mouse Models of Cancer: Immunotherapy of Tumors with Different MHC-I Expression Patterns
    Natalia Aptsiauri et al, 2013, MHC Class I Antigens In Malignant Cells CrossRef